Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia. (3rd July 2017)

• Record Type: Journal Article
• Authors: Tabe, Yoko; Tafuri, Agostino; Sekihara, Kazumasa; Yang, Haeun; Konopleva, Marina
• Is Part Of: Expert opinion on therapeutic targets. Volume 21:Number 7(2017:Jul.)
• Page Start: 705
• Page End: 714
• Publication Date: 2017-07-03
• Subjects: Acute myeloid leukemia (AML) -- mTORC1/2 dual inhibitor -- leukemia stem cells -- PI3K/AKT/mTOR pathway -- self-renewal -- tumor microenvironment; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2017.1333600
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction : Acute myeloid leukemia (AML), the most common acute leukemia in adults, remains a therapeutic challenge. The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway is one of the key aberrant intracellular axes involved in AML. Areas covered : mTOR plays a critical role in sensing and responding to environmental determinants such as nutrient availability, stress, and growth factor concentrations; and in modulating key cellular functions such as proliferation, metabolism, and survival. Although abnormalities of mTOR signaling are strongly associated with neoplastic leukemic proliferation, the role of pharmacologic inhibitors of mTOR in the treatment of AML has not been established. Expert opinion : Inhibition of mTOR signaling has in general modest growth-inhibitory effects in preclinical AML models and clinical trials. Yet, combination of allosteric mTOR inhibitors with standard chemotherapy or targeted agents has a greater anti-leukemia efficacy. In turn, dual mTORC1/2 inhibitors, and dual PI3K/mTOR inhibitors show greater activity in pre-clinical AML models. Further, understanding the role of mTOR signaling in stemness of leukemias is important because AML stem cells may become chemoresistant by displaying aberrant signaling molecules, modifying epigenetic mechanisms, and altering the components of the bone marrow microenvironment.